Best Canadian Companies To Own In Right Now

Last week, the Canadian government announced�that it will enforce more stringent standards for pipelines under its jurisdiction.

The Honorable Joe Oliver, Canada's Minister of Natural Resources, said that pipelines will need to have the financial capability to "respond to any incident and remedy damage."

Major crude oil pipelines, for instance, must have "a minimum financial capability of $1 billion," he said. He also announced additional measures, including new safety rules for pipeline operators and new financial penalties for violators, which are set to come into effect shortly.

According to Canada's Department of Natural Resources, some of these additional measures include:

1) New fines that will soon come into force that will preventatively address contraventions quickly so that larger issues do not arise in the future. The penalties to companies and individuals for a range of infractions can range from $25,000 to a maximum of $100,000;
2) Requiring companies to appoint an accountable senior officer whose duty is to ensure their management system and programs are in compliance;
3) Ensuring companies' emergency and environmental plans are transparent and easily available to the public; and
4) Enshrining in law the 'polluter pays' principle explicitly in law. Currently it is only implicit; Some pipelines are regulated by the federal government and others by the province.

Why pipeline safety is crucial
The announcement came at the end of a month in which a seemingly unusual number of Canadian pipeline spills were reported. In early June, Apache (NYSE: APA  ) reported�a pipeline spill in northern Alberta that released 2.5 million gallons of contaminated water, impacting an area of about 100 acres.

Best Canadian Companies To Own In Right Now: Omeros Corporation(OMER)

Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its product candidates are derived from its proprietary PharmacoSurgery platform that is designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological, and other surgical and medical procedures. The company?s lead PharmacoSurgery product candidates include OMS103HP, a Phase 3 clinical program evaluated for OMS103HP?s safety and ability to improve postoperative joint function and reduce pain following arthroscopic partial meniscectomy surgery, and arthroscopic anterior cruciate ligament; OMS302, a Phase 2b clinical trial completed product candidate for use during ophthalmological procedures, including cataract and other lens replacement surgery; and OMS201, a Phase 1/Phase 2 clinical trial completed program for use durin g urological surgery. It also engages in developing proprietary compositions that comprise peroxisome proliferator-activated receptor gamma agonists for the treatment and prevention of addiction to substances of abuse. The company?s pipeline of preclinical product development programs includes Plasmin for Surgical and traumatic bleeding; PDE7 for addictions and compulsive disorders, and movement disorders; MASP-2 for macular degeneration, ischemia-reperfusion injury, transplant surgery, and radiation injury; and PDE10 for Schizophrenia. Omeros Corporation was founded in 1994 and is based in Seattle, Washington.

Best Canadian Companies To Own In Right Now: Tranzyme Inc.(TZYM)

Tranzyme, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of acute and chronic gastrointestinal (GI) motility disorders in the United States and internationally. The company?s clinical product candidates include ulimorelin, an intraveneous ghrelin agonist, which is in the Phase III clinical development stage for the treatment of acute upper GI motility disorders; and TZP-102, an orally-administered ghrelin agonist that has commenced Phase IIb clinical development stage for the treatment of diabetic gastroparesis. Its preclinical product candidates comprise TZP-201, a motilin antagonist for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, an oral ghrelin antagonist for the treatment of metabolic diseases. The company has strategic collaboration with Bristol-Myers Squibb Company to discover, develop, and commercialize additional novel co mpounds; and a license agreement with Norgine B.V to develop and commercialize ulimorelin in Europe, Australia, New Zealand, the Middle East, and north and South Africa. Tranzyme, Inc. was founded in 1998 and is headquartered in Durham, North Carolina.

Advisors' Opinion:

• [By Roberto Pedone]

  Tranzyme (TZYM), a biopharmaceutical company, engages in the discovery, development and commercialization of mechanism-based therapeutics primarily in the U.S. This stock closed up 6% at 55 cents on Thursday.

  Thursday's Range: $0.49-$0.58
  
  52-Week Range: $0.40-$5.16
  
  Volume: 667,000
  
  Three-Month Average Volume: 490,321

  From a technical perspective, TZYM bounced higher here right off its 50-day moving average at 50 cents with above-average volume. This stock has been trending sideways in a consolidation chart pattern for the last three months, with shares moving between 68 cents on the upside and 40 cents on the downside. This spike today is quickly pushing shares of TZYM within range of triggering a major breakout trade. That trade will hit if TZYM manages to take out some near-term overhead resistance levels at 57 to 60 cents with high volume.

  Traders should now look for long-biased trades in TZYM as long as it's trending above its 50-day at 50 cents and then once it sustains a move or close above those breakout levels with volume that hits near or above 490,321 shares. If that breakout triggers soon, then TZYM will set up to re-test or possibly take out its next major overhead resistance levels at 65 to 68 cents. Any high-volume move above 68 cents will then put its next major overhead resistance levels at 74 to 82 cents into range for shares of TZYM.

Top Stocks To Invest In Right Now: Aspial Corporation Limited (A30.SI)

Aspial Corporation Limited, an investment holding company, engages in the manufacture, wholesale, retail, and export of jewelry. It offers fine contemporary jewelry principally under the Lee Hwa, Goldheart, and CitiGems brand names. The company also engages in property investment, development, and management; investment holding; building construction and contracting; and pawn broking activities. It specializes in the development, marketing, and management of small to medium sized apartments. Aspial Corporation operates 22 pawnshops. The company was formerly known as Lee Hwa Holdings Pte Ltd. and changed its name to Aspial Corporation Limited in 2001. The company was incorporated in 1970 and is based in Singapore. Aspial Corporation Limited is a subsidiary of MLHS Holdings Pte Ltd.